- $927.45m
- $718.55m
Annual cashflow statement for Compass Therapeutics., fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -82.2 | -39.2 | -42.5 | -49.4 | -66.5 |
| Depreciation | |||||
| Non-Cash Items | 55.7 | 5.58 | 4.08 | 8.07 | 6.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 6.25 | -1.26 | -2.91 | -4.14 | 9.18 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -19.7 | -34.1 | -40.6 | -44.9 | -49.1 |
| Capital Expenditures | -1.89 | -0.212 | -0.03 | -0.044 | -0.025 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.116 | -151 | 27 | 46.8 | -93.3 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.77 | -151 | 27 | 46.8 | -93.3 |
| Financing Cash Flow Items | -0.281 | -0.495 | -0.253 | -0.775 | -9.66 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 119 | 75.8 | 2.94 | 17.3 | 130 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 97.2 | -110 | -10.7 | 19.3 | -12.8 |